Anesthesia Pharmacology 
Chapter 7:  Autonomic Cholinergic Pharmacology Practice Questions
	Click on the correct answer.
 
 
 
- Location(s) of cholinergic synaptic sites: -   neuromuscular junction
-   autonomic effector sites innervated by post-ganglionic sympathetic fibers
-   some CNS synapses
-   A & C
-   B & C
 
- Factors that limit CNS effects of systemic acetylcholine: administration: -   poor CNS penetration
-   inactivation by plasma butrylcholinesterase
-   both
-   neither
 
- Localization of muscarinic cholinergic receptors: -   postganglionic parasympathetic effector sites
-   autonomic ganglia cells
-   adrenal medulla
-   A & C
-   A, B & C
 
- Cholinergic receptor type primarily localized at skeletal muscle neuromuscular junctions: -   muscarinic
-   nicotinic
 
- Highly sensitive to the action of acetylcholinesterase: -   carbachol
-   bethanechol (Urecholine)
-   acetylcholine
-   A & C
-   A,B, & C
 
- Muscarinic receptor subtype primarily associated with the heart: -   M1
-   M2
-   M3
-   M4
 
- Effective antagonist at neuromuscular junction receptors; -   atropine
-   tubocurarine
 
- Most likely to be effective in blocking all ganglionic neurotransmission: -   tubocurarine
-   mecamylamine (Inversine)
-   atropine
-   all of the above
 
- Cardiac muscarinic Type M2-receptor mediated action(s): -   increased phase 4 depolarization rate
-   increased AV nodal conduction velocity
-   Decreased atrial and ventricular contractility
-   all the above
 
- Ligand-gated ion channels: -   nicotinic
-   muscarinic
-   both
-   neither
 
- Tends to cause fast responses: -   nicotinic
-   muscarinic
 
- Agonist effects blocked by tubocurarine: -   muscarinic receptors
-   nicotinic receptors
 
- Indirect-acting cholinomimetic: -   atropine
-   edrophonium (Tensilon)
-   carbachol
-   acetylcholine
-   ephedrine